Completed PHASE1 NCT00002116
A Phase I/II Study of the Safety and Efficacy of Topical 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) in the Treatment of Refractory Mucocutaneous Herpes Simplex Disease in Patients With AIDS
Sponsor: Gilead Sciences
Conditions
HIV Infections Herpes Simplex
Interventions
Cidofovir
Updated 5 times since 2017 Last updated: Jun 23, 2005
A PHASE1 clinical study on HIV Infections and Herpes Simplex, this trial is completed. The trial is conducted by Gilead Sciences and has accumulated 5 data snapshots since 2026. Infectious disease trials contribute critical data for public health response and treatment development.
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Gilead Sciences
Data source: NIH AIDS Clinical Trials Information Service
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Baltimore, United States
- • Chapel Hill, United States
- • Chicago, United States
- • Houston, United States
- • Los Angeles, United States
- • San Francisco, United States
- • Seattle, United States
- • Vancouver, Canada